Sarasota, Fla. (Aug. 26, 2025) – Women with advanced or recurring ovarian, peritoneal, or fallopian tube cancer may be eligible to participate in a new clinical trial offered by Sarasota Memorial’s Kolschowsky Research and Education Institute.
Led locally by principal investigator Beverly Long, MD, and sub-investigator Toni Kilts, DO, gynecologic oncology surgeons with SMH’s First Physicians Group and Brian D. Jellison Cancer Institute,
the research study is testing different dosing schedules for the investigational drug Mirvetuximab Soravtansine in women with platinum-resistant ovarian cancer and related cancers. The cancer drug targets the protein folate receptor-alpha, or FR-alpha, which is found in high levels on many ovarian, fallopian tube, and primary peritoneal cancer cells.
By targeting FR-alpha, Mirvetuximab Soravtansine is designed to identify these cancer cells more precisely, while limiting damage to nearby healthy cells. By testing different dosing schedules, the study aims to elevate the clinical benefit of the treatment with a convenient dosing schedule.
Who may qualify:
- Women with high-grade ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy
- Tumors that show high levels of the protein called folate receptor-alpha (FRα) as determined by an FDA approved test
- Cancer that has continued to grow or spread after previous platinum-based chemotherapy
For more information or to find out if you are eligible to participate in the local study, contact Kolschowsky Institute research team at (941) 917-2225 or researchinstitute@smh.com.
For more information about the national trial, click here.